CorMedix Inc. (CRMD)

7.07
0.26 3.55
AMEX : Health Technology
Prev Close 7.33
Open 7.32
Day Low/High 6.97 / 7.49
52 Wk Low/High 0.86 / 13.70
Volume 337.08K
Avg Volume 1.49M
Exchange AMEX
Shares Outstanding 23.80M
Market Cap 160.43M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
CorMedix Provides Regulatory Update For CRMD003 (Neutrolin®)

CorMedix Provides Regulatory Update For CRMD003 (Neutrolin®)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has...

CorMedix Announces SPA Agreement With FDA For Phase 3 Trial In The Prevention Of Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Announces SPA Agreement With FDA For Phase 3 Trial In The Prevention Of Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it has ...

CorMedix Announces Successful Completion Of Patient Recruitment In Phase II Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Announces Successful Completion Of Patient Recruitment In Phase II Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it ...

CorMedix Reports First Quarter 2011 Financial Results

CorMedix Reports First Quarter 2011 Financial Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its ...

CorMedix Announces Interim Analysis & Clinical Update For Phase II Study Of CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Announces Interim Analysis & Clinical Update For Phase II Study Of CRMD001 (A Proprietary Formulation Of Deferiprone)

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its ...

CorMedix Reports Year End 2010 Financial Results

CorMedix Reports Year End 2010 Financial Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its ...

CorMedix Appoints Mark A. Klausner, M.D. As Chief Medical Officer

CorMedix Appoints Mark A. Klausner, M.D. As Chief Medical Officer

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced the ...

CorMedix To Present At 13th Annual BIO CEO And Investor Conference

CorMedix To Present At 13th Annual BIO CEO And Investor Conference

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is...

CorMedix Statement On Today’s Market Activity

CorMedix Statement On Today’s Market Activity

In view of the unusual market activity in the stock of CorMedix Inc.

CorMedix Provides Year End Summary Of 2010 Achievements

CorMedix Provides Year End Summary Of 2010 Achievements

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today provided a ...

CorMedix To Present At The Maxim Group Growth Conference

CorMedix To Present At The Maxim Group Growth Conference

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is...

CorMedix Reports Third Quarter 2010 Results And Provides Business Update

CorMedix Reports Third Quarter 2010 Results And Provides Business Update

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced its ...

CorMedix Awarded Grants From Federal Qualifying Therapeutic Discovery Project Program

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it has...

LifeSci Advisors Announces Investment Opinion On CorMedix Inc.

LifeSci Advisors Announces Investment Opinion On CorMedix Inc.

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of CorMedix Inc.

CorMedix To Present At BIO Investor Forum Conference

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is...

CorMedix To Present At The Rodman & Renshaw Annual Global Investment Conference

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced it is...

CorMedix Reports Second Quarter 2010 Results

CorMedix Reports Second Quarter 2010 Results

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced its ...

CorMedix Announces Appointment Of Key Positions

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced the ...

CorMedix Statement On Today’s Market Activity

In view of the unusual market activity in the stock of CorMedix Inc.

CorMedix Added To Russell Microcap® Index

CorMedix Added To Russell Microcap® Index

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced that ...

CorMedix Doses First Patient In Phase II Clinical Trial Of CRMD-001

CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of Cardiorenal disease, today announced dosing...

TheStreet Quant Rating: D (Sell)